Carlos Zamora, MD
Cardiovascular Disease · Fleming Island, FLNPI 1023314952
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $89,973 of the $110,378 with a category attached, or 81.5%. 25 manufacturers reported payments, led by Boehringer Ingelheim at 49.3% of the total. Reporting peaked in 2019 at $41,217 and has fallen 99.6% since, to $176 in 2023. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 245 payments — averaging $450.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$54K
- Lilly USA, LLC$45K
- Amarin Pharma, Inc.$4K
- Sanofi-aventis U.S. LLC$3K
- Abbott$2K
- Amgen$181
- plus $1K from 19 others
Across 13 payments — averaging $5766.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$75K
What the payments were for
- Consulting fees$8,6108%
- Speaking & faculty fees$89,97382%
- Travel & lodging$6,2626%
- Food & beverage$5,4585%
- Education$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 64 | $54,417 |
| Lilly USA, LLC | 50 | $45,049 |
| Amarin Pharma, Inc. | 16 | $4,411 |
| Sanofi-aventis U.S. LLC | 10 | $3,270 |
| Abbott | 34 | $1,711 |
| Amgen | 12 | $181 |
| Novartis | 10 | $168 |
| Novo Nordisk | 3 | $165 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $164 |
| Edwards Lifesciences | 1 | $122 |
| Bard Peripheral Vascular, Inc. | 1 | $122 |
| Pfizer | 8 | $110 |
| Merck | 5 | $94 |
| Biotronik Inc. | 1 | $76 |
| Boston Scientific | 2 | $68 |
| AstraZeneca | 3 | $43 |
| Johnson & Johnson | 3 | $37 |
| Medtronic | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Lundbeck LLC | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Celonova Biosciences, Inc. | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$98,593
- Vascepa$3,991
- DISEASE STATE$3,023
- Mitra Clip system$722
- AMPLATZER Occluders$158
- Ozempic$125
- MitraClip System$123
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$122
- CardioMEMS HF System$117
How this compares
$110,378 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Fleming Island
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.